Press Release   -

Acute Repetitive Seizures Market to Reach Valuation of USD 998.1 Million by 2028 - Increasing in Launch of New Advanced Treatments Is Driving the Market

In terms of revenue, the Global Acute Repetitive Seizures Market is expected to reach USD 998.1 Million by 2028, growing at a CAGR of 47.5% from 2022 to 2028. An increase in the number of clinical trials has led to the launch of new treatments, and the rise in demand for nasal sprays for the cure of epilepsy is the major reason influencing the expansion of the Acute Repetitive Seizures Market throughout the world. Also, an escalation in the number of administrative licenses and promising drugs in the channel is anticipated to boost the growth of the Acute Repetitive Seizures Market in the forecasted period.

Key Findings:

• The diastat rectal gel sub-segment is anticipated to dominate the segment for Acute Repetitive Seizures Market and grow at a substantial CAGR. The rise in adoption is due to its efficiency and of FDA-approved drugs in the market.
• ‘The healthcare & pharmaceuticals sub-segment held a market significant share in 2021. This is due to the growing investments in research and development in the domain of neurology, funds by the management, and surge in requirement for medicines for epilepsy.
• North America is the largest regional segment. This surge is attributed to the rising demand for Acute Repetitive Seizures drug in developed economies such as U.S. and Canada.

Some of key players in Acute Repetitive Seizures Market includes - Alexza Pharmaceuticals, Bausch Health, Neurelis, Pfizer Inc., Sanofi, UCB S.A.,Valeant Pharmaceuticals North America LLC., Veriton Pharma.

To constrain healthcare expenditure, management across the world is making constant measures to decrease hospital stays and on-site patient therapy expenses through outpatient care prototypes, like clinic and home healthcare facilities. This factor is assumed to drive the growth of the Acute Repetitive Seizures Market. The classification of seizures, epilepsies, and epilepsy syndromes creates a framework for clinicians, researchers, and patients and their families. This classification has evolved over the years, and in 2017 the International League Against Epilepsy (ILAE) published an operational classification of seizures and epilepsies. Understanding this classification is important in the diagnosis, treatment, and understanding of seizures and epilepsies, including epilepsy incidence.

Asia Pacific is expected to record the highest CAGR, owing to the increasing demand in countries, such as China, Japan, and India. As there have been technological improvements in the scientific, clinical, and medical sectors due to the increase in demand for antiepileptic drugs. Government initiatives are taken to enhance the quality of life and understanding about the disease, associated with the promotion of a better healthcare system are the major drivers stimulating the market growth in this region.

COVID Impact Analysis

The COVID-19 outbreak has affected various industries worldwide. Governments across the world implemented strict lockdown measures and social distancing norms in order to restrict the swift spread of the pandemic. Manufacturing facilities around the world were shut down during the initial stages of the pandemic. Moreover, the economic crisis after the pandemic might lead to a significant delay in the commercial roll-out of the Acute Repetitive Seizures Market. Small and medium-scale companies are the backbone of technology providers and are witnessing a steep drop in revenue since the emergence of the pandemic in 2020. Hence, market players faced numerous challenges as disruptions in the supply chain were observed. However, things will improve in the second half of 2022 as more supplies will come online.